CoChat

Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization

Open access
Soliman, Wael, Lund‐Andersen, Henrik, Larsen, Michael · 2006 · Acta Ophthalmologica Scandinavica
Cited by 202

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

A 32-year-old woman presented with loss of stereopsis and blurred vision in the right eye of 1 month's duration. A documented gradual loss of best corrected visual acuity (BCVA) in the right eye had occurred during this period, from 0.9 at onset to 0.16 at presentation in our institution. Best corrected VA in the left eye was 1.0 and refraction was − 5.0 dioptres in both eyes. The right eye demonstrated a serous detachment of the entire macula and extensive subretinal haemorrhage from a peripapillary choroidal neovascularization (PCNV), the apparent origin of which was an area of peripapillary atrophy (Fig. 1). The left fundus was normal except for a small temporal sector of peripapillary atrophy. Photocoagulation and photodynamic therapy were deferred because the PCNV was poorly delineated in angiography and partially obscured by haemorrhage. The patient received a 1-week course of prednisolone 1 mg/kg, after which the serous detachment and the subretinal haemorrhage were seen to have increased. Subjectively, vision had deteriorated further, although objectively BCVA in the right eye remained at 0.16. We advised the patient that the prognosis for spontaneous visual recovery was poor and that the likely prospect with photocoagulation only was visual stabilization. Because of her critical professional need for stereopsis, the patient was offered and accepted open-label treatment using 1 mg (0.04 ml) intravitreal bevacizumab (Avastin; Roche, Copenhagen, Denmark). The intravitreal injection was given via the pars plana after preparation of the eye with 5% povidone/iodine, topical antibiotics and topical anaesthesia. The study protocol conformed with Danish law and adhered to the tenets of the Declaration of Helsinki. The patient was followed weekly for 3 months, during which complete resolution of the serous detachment, near-complete resorption of the subretinal haemorrhage and recovery of BCVA to 1.0 in the right eye were noted (1, 2). No adverse effects were seen other than subconjunctival haemorrhage immediately after injection. (A) Colour and (B) red-free greyscale fundus photography, and (C) late-phase fluorescein angiography of the right eye of a woman aged 32 years with subretinal peripapillary choroidal neovascularization. Baseline pictures (top row) show the eye after 1 week of systemic prednisolone therapy; subretinal serous fluid, haemorrhage and a leaking neovascular membrane are seen. Three weeks after intravitreal injection of bevacizumab (second row), a definite reduction in fluid, haemorrhage and leakage is seen. At 8 weeks (third row) the fluid has disappeared, the blood has been almost completely resorbed, and the neovascular membrane has ceased to leak, although it continues to stain. At 12 weeks (fourth row) the blood has completely disappeared and the size of the neovascular membrane is decreased. (A) Horizontal and (B) vertical transfoveal optical coherence tomography scans of the right eye of the subject, before intravitreal bevacizumab injection and at 3, 8, and 12 weeks after injection (top, second, third and fourth row respectively). Before injection, serous subretinal fluid and an indistinguishable mixture of haematoma and new vessels are seen to involve the entire macula. After injection of bevacizumab, a gradual and steady process of resolution is seen; at 12 weeks the most prominent finding is an elevated mound of retinal pigment epithelium with internal hyperreflectivity at the apparent site of origin of the neovascular membrane. Peripapillary choroidal neovascularization can lead to loss of central vision if blood, exudate or new vessels extend under the fovea. The condition may be associated with age-related macular degeneration (AMD), multifocal choroiditis, angioid streaks, histoplasmosis scars, choroidal osteoma, optic disc drusen, congenital disc anomalies, pattern dystrophy, and peripapillary pseudopodal pigment epithelial and choroidal atrophy. About half of the cases show no obvious primary underlying condition and may be categorized as idiopathic (Browning & Fraser 2005). Bevacizumab is an inhibitor of vascular endothelial growth factor approved for the treatment of metastatic colorectal cancer (Hurwitz et al. 2004). In subfoveal neovascular AMD or myopia, small uncontrolled studies of systemic or intravitreal bevacizumab treatment have shown favourable outcomes (Michels et al. 2005; Nguyen et al. 2005; Rosenfeld et al. 2005). The natural history of PCNV is poorly described, whereas the course after photocoagulation treatment has been documented in an uncontrolled case series, where the average non-AMD patient was found to experience stabilization of baseline VA but a high frequency of PCNV recurrence without further treatment (Browning & Fraser 2005). Spontaneous involution of PCNV leakage can occur, but in our case the onset of improvement within 1 week of bevacizumab injection and the near-complete remission within 3 months suggest that the bevacizumab may have contr

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-0420.2006.00736.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 202

Metadata

Authors
Soliman, W., Lund‐Andersen, H., & Larsen, M.
Venue
Acta Ophthalmologica Scandinavica
Publisher
Wiley
Published
2006-06-22
Volume
84
Issue
5
Pages
707-708
ISSN
  • 1395-3907 (ISSN-L)
  • 1600-0420
OpenAlex
W1966488092
Cited by
202
References
1
FWCI
15.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.